Chemoimmunotherapy regimen

This page covers all Chemoimmunotherapy regimen drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD20.

Targets

CD20

Phase 3 pipeline (1)

• R-FM · Fondazione Italiana Linfomi - ETS · Oncology
  R-FM is a rituximab-based chemoimmunotherapy regimen combining rituximab with fludarabine and mitoxantrone for B-cell lymphomas.